Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Total 13F shares
-
49,755,427
-
Share change
-
+10,936,718
-
Total reported value
-
$83,955,640
-
Put/Call ratio
-
131%
-
Price per share
-
$1.69
-
Number of holders
-
127
-
Value change
-
+$17,804,458
-
Number of buys
-
62
-
Number of sells
-
38
Institutional Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q3 2023
As of 30 Sep 2023,
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) was held by
127 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,755,427 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., ARMISTICE CAPITAL, LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, CREDIT SUISSE AG/, JPMORGAN CHASE & CO, NORTHERN TRUST CORP, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, and NATIONAL BANK OF CANADA /FI/.
This page lists
128
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.